Enabling Rapid, Scientifically Sound Decision-Making
Our portfolio of Translational Platforms for oncology, inflammation and cardiovascular and metabolic disease (CVMD) provide insight and understanding about a drug's efficacy, pharmacological profile and patient response profile, reducing failure in the clinic, and supporting the selection of the right patients for the right therapy.
CrownBio’s fast-paced R&D programs are yielding novel, yet well-validated models at the cutting-edge of disease research. Our unique MuPrime™ models, as well as human target expressing models (HuGEMM™) and hematopoietic stem cell (HSC) – patient-derived xenograft (PDX) models are leading the way in advanced immuno-oncology, whilst the development of NASH NHP and rodent models are providing unique platforms for CVMD drug discovery.
Drive Your Next Clinical Success
Read why PDX models and their use in human-surrogate Phase II-like trials are changing the paradigm for oncology drug development and biomarker discovery today.
What are the big challenges in the development of the next generation of drugs to treat metabolic diseases? Discover why drug discovery organizations are turning to our NHP and rodent models to help find their antidiabetic drugs of the future.
We’re inspired to help our clients. Let’s talk about how we can help you.